Why the study?
Do drug-eluting stents reduce late lumen loss, binary restenosis, and target vessel revascularization in diabetic patients undergoing percutaneous coronary intervention compared to bare-metal stents?
Do drug-eluting stents reduce late lumen loss, binary restenosis, and target vessel revascularization in diabetic patients undergoing percutaneous coronary intervention compared to bare-metal stents?
Drug-eluting stents are the preferred option for diabetic patients undergoing percutaneous coronary intervention due to improved safety and efficacy compared to bare-metal stents.
Answers are grounded in this paper and cite their sources.
Supports DES preference in diabetic PCI for lower restenosis; leaves open durability versus contemporary platforms and OMT.
The relationship between diabetes mellitus and coronary artery disease is well established. The percentage of patients participating in clinical trials of percutaneous coronary intervention who have diabetes is quickly rising. Diabetic patients have a worse prognosis than nondiabetic patients, with generally greater rates of death, myocardial infarction and need for target lesion and vessel revascularization. Stenting has improved the outcome of diabetic patients receiving percutaneous coronary intervention. Compared with bare-metal stents, the use of drug-eluting stents in diabetic patients has resulted in a significant reduction in late lumen loss, binary restenosis, and clinically driven target vessel revascularization. The safety and efficacy of drug-eluting stents in diabetic patients is now well established; they are the preferred option in this subgroup in the absence of contraindications. New stent designs, polymers and drugs are resulting in better outcomes overall, but more research is required ...
No takes yet. Share an insight, caveat, or question.
Stuckey et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: